Navigation Links
Takeda Enters Into Global Strategic Partnerships With Covance and Quintiles
Date:2/15/2011

DEERFIELD, Ill., Feb. 15, 2011 /PRNewswire/ -- Takeda Pharmaceuticals International, Inc., a wholly-owned subsidiary of Takeda Pharmaceutical Company Limited, today announced that its Pharmaceutical Development Division has entered into strategic partnerships with Covance (NYSE: CVD) and Quintiles, two of the world's largest full-service contract research organizations.

Under terms of the agreements, Covance and Quintiles will work in close partnership with Takeda to plan and execute global development programs to support new compounds in all therapeutic areas, except oncology. Takeda will have access to the clinical development capabilities and central laboratory services of Covance and Quintiles, with each partner company providing dedicated resources to support Takeda's development pipeline. Takeda intends to use a global program-level sourcing strategy to increase operational efficiency. Through these relationships, Takeda will move toward a fully virtual outsourcing model combining the expertise and capabilities of Takeda with those of Covance and Quintiles to improve productivity and facilitate Takeda's global growth.  

"Takeda is focused on growing its global drug development footprint, especially in Asia, while at the same time ensuring quality and increasing efficiency of our operations," said Robert Ahlbrandt, Ph.D., senior vice president, global development operations for Takeda's Pharmaceutical Development Division. "Our new strategic partnerships with Covance and Quintiles will improve the agility and productivity of our drug development activities, helping us to deliver innovative new medicines to patients globally."

About Takeda Pharmaceuticals International, Inc.

Located in Deerfield, Illinois, Takeda Pharmaceuticals International, Inc. is a wholly-owned subsidiary of Takeda Pharmaceutical Company Limited, an industry leader and the largest pharmaceutical company in Japan. Takeda Pharmaceuticals International, Inc. is the hub for R&D excellence and the commercial activities in Americas and Europe as well as other strategic functions of Takeda group. It is committed to maximize the global market potential of new products and the company's international presence to realize Takeda's Mission to strive toward better health for patients through leading innovation in medicine. Additional information about Takeda is available through its corporate Web site, www.takeda.com.


'/>"/>
SOURCE Takeda Pharmaceuticals International, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Takeda Completes Settlements With All Defendants in U.S. Patent Litigation Involving ACTOS® (pioglitazone HCI), ACTOplus met® (pioglitazone HCl and metformin HCl) and duetact® (pioglitazone HCl and glimepiride)
2. Takeda Responds to Announcement about Suspension of Rosiglitazone Marketing Authorization in Europe and Restrictions in the U.S.
3. Arthritis Foundation and Takeda Launch First-Ever National Gout Public Service Announcement (PSA) Campaign, Urging People Living With Gout to Keep Enjoying Lifes Simple Pleasures
4. Orexigen® Therapeutics and Takeda Enter Into Partnership to Commercialize Contrave® in North America
5. Takeda Responds to FDA Advisory Committee Recommendation
6. Takeda Provides Update on Patent Litigation for ACTOS(R) (pioglitazone HCl) and ACTOplus met(R) (pioglitazone HCl and metformin HCl) in the U.S.
7. CellCentric Licenses Novel Epigenetic Discovery Programme to Takeda
8. Amylin and Takeda Announce Decision to Advance Development of Pramlintide/Metreleptin Combination Treatment for Obesity
9. Takeda Announces Initiation of Trial to Study the Concomitant Use of Dexlansoprazole and Other Proton Pump Inhibitors with Plavix(R) (clopidogrel bisulfate)
10. Emerging Agents from Theravance/Astellas, Johnson & Johnson/Basilea and Forest/Astrazeneca/Takeda Will Drive Modest Growth in the MRSA Drug Market Through 2018
11. Takeda San Francisco, Inc. Appoints Michael Buckley, Ph.D. Vice President of Process Sciences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2017)... , March 27, 2017  Sanderling Ventures, portfolio ... Ethicon, a division of Johnson & Johnson. Torax manufactures ... the treatment of gastro-esophageal reflux disease (GERD). The ... (MSA) technology and the procedure is currently available ... Torax Medical was founded by Sanderling Ventures, ...
(Date:3/27/2017)... FinancialBuzz.com News Commentary  ... According to a new report by Arcview Market Research, the ... 34 percent to $6.7 billion and can be expected to grow at ... five years, from $6.7 billion in 2016, to $22.6 billion in 2021. ... to purchase cannabis without a doctor,s recommendation. Voters in California ...
(Date:3/27/2017)... 2017 The staggering cost of cancer treatment ... access to the latest treatment options against cancer. Even ... patients have inadequate or no health insurance and are ... Access to modern cancer treatment is almost non-existent for ... The mission statements of pharmaceutical and biotech companies ...
Breaking Medicine Technology:
(Date:3/28/2017)... ... 2017 , ... Award-winning medical group Allied Anesthesia today announced ... chair for Orange County health care system CalOptima Friday. CalOptima announced its election ... Mark Refowitz’s term, which runs through June 30 of this year, until another ...
(Date:3/28/2017)... ... March 28, 2017 , ... In its ... Success website has recently developed and published an informational resource that addresses frequently ... based on common inquiries the site’s team of third party administrator (TPA) contributors ...
(Date:3/28/2017)... CA (PRWEB) , ... March 28, 2017 , ... ... Carson Liu of SkyLex Advanced Surgical, Inc. is thrilled to offer the recently ... balloon procedure, and this procedure adds to SkyLex Advanced Surgical’s already comprehensive ...
(Date:3/28/2017)... ... , ... Oily skin is a common and unwelcomed occurrence in people of all ages, genders ... offer to the discussion of dealing with excess skin oil. “Oily skin is a challenge ... that can help remove the oily shine while keeping the skin fresh and clean,” says ...
(Date:3/27/2017)... ... 27, 2017 , ... New patients who have sleep apnea in ... or without a referral. Sleep apnea is often left untreated because patients are not ... and chronic snoring. , Dr. Braasch seeks to raise awareness of sleep apnea ...
Breaking Medicine News(10 mins):